BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
69.71
-4.81 (-6.45%)
At close: Apr 28, 2026, 4:00 PM EDT
70.25
+0.54 (0.77%)
After-hours: Apr 28, 2026, 5:13 PM EDT
BridgeBio Pharma Employees
As of December 31, 2025, BridgeBio Pharma had 839 total employees, including 834 full-time and 5 part-time employees. The number of employees increased by 109 or 14.93% compared to the previous year.
Employees
839
Change (1Y)
109
Growth (1Y)
14.93%
Revenue / Employee
$598,422
Profits / Employee
-$864,042
Market Cap
13.51B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 4,700 |
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
BBIO News
- 6 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - GlobeNewsWire
- 4 weeks ago - BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - GlobeNewsWire
- 5 weeks ago - BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - GlobeNewsWire
- 6 weeks ago - BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
- 6 weeks ago - BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - GlobeNewsWire
- 6 weeks ago - BridgeBio Pharma Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga